Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 67, 5418-5424, June 1, 2007. doi: 10.1158/0008-5472.CAN-06-4322
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gomez-Bougie, P.
Right arrow Articles by Amiot, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gomez-Bougie, P.
Right arrow Articles by Amiot, M.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Noxa Up-regulation and Mcl-1 Cleavage Are Associated to Apoptosis Induction by Bortezomib in Multiple Myeloma

Patricia Gomez-Bougie1,3, Soraya Wuillème-Toumi1,2,3, Emmanuelle Ménoret1,2,3, Valérie Trichet2,4, Nelly Robillard1, Moreau Philippe2,5, Régis Bataille1,2,3 and Martine Amiot1,2,3

1 Institut National de la Sante et de la Recherche Medicale, UMR601; 2 Université de Nantes, Nantes Atlantique Universités, UFR Médecine et Techniques Médicales; 3 Equipe 5 labélisée Ligue Nationale contre le Cancer 2005; 4 Institut National de la Sante et de la Recherche Medicale ERI 7; 5 Centre Hospitalier Universitaire, Service d'Hématologie Clinique, Nantes, France

Requests for reprints: Martine Amiot, Institut National de la Sante et de la Recherche Medicale, U601, Département de recherche en Cancérologie, 9 quai Moncousu, Nantes, F-44000 France. Phone: 33-2-40-08-47-66; Fax: 33-2-40-08-47-78; E-mail: mamiot{at}nantes.inserm.fr.

Targeting the ubiquitin-proteasome pathway has emerged as a potent anticancer strategy. Bortezomib, a specific proteasome inhibitor, has been approved for the treatment of relapsed or refractory multiple myeloma. Multiple myeloma cell survival is highly dependent on Mcl-1 antiapoptotic molecules. In a recent study, proteasome inhibitors induced Mcl-1 accumulation that slowed down their proapoptotic effects. Consequently, we investigated the role of Bcl-2 family members in bortezomib-induced apoptosis. We found that bortezomib induced apoptosis in five of seven human myeloma cell lines (HMCL). Bortezomib-induced apoptosis was associated with Mcl-1 cleavage regardless of Mcl-1L accumulation. Furthermore, RNA interference mediated Mcl-1 decrease and sensitized RPMI-8226 HMCL to bortezomib, highlighting the contribution of Mcl-1 in bortezomib-induced apoptosis. Interestingly, an important induction of Noxa was found in all sensitive HMCL both at protein and mRNA level. Concomitant to Mcl-1 cleavage and Noxa induction, we also found caspase-3, caspase-8, and caspase-9 activation. Under bortezomib treatment, Mcl-1L/Noxa complexes were highly increased, Mcl-1/Bak complexes were disrupted, and there was an accumulation of free Noxa. Finally, we observed a dissociation of Mcl-1/Bim complexes that may be due to a displacement of Bim induced by Noxa. Thus, in myeloma cells, the mechanistic basis for bortezomib sensitivity can be explained mainly by the model in which the sensitizer Noxa can displace Bim, a BH3-only activator, from Mcl-1, thus leading to Bax/Bak activation. [Cancer Res 2007;67(11):5418–24]




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
C. Li, R. Li, J. R. Grandis, and D. E. Johnson
Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells
Mol. Cancer Ther., June 1, 2008; 7(6): 1647 - 1655.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Tse, A. R. Shoemaker, J. Adickes, M. G. Anderson, J. Chen, S. Jin, E. F. Johnson, K. C. Marsh, M. J. Mitten, P. Nimmer, et al.
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Cancer Res., May 1, 2008; 68(9): 3421 - 3428.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
K. Kandasamy and A. S. Kraft
Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region
Mol. Cancer Ther., May 1, 2008; 7(5): 1091 - 1100.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Nefedova, D. M. Sullivan, S. C. Bolick, W. S. Dalton, and D. I. Gabrilovich
Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy
Blood, February 15, 2008; 111(4): 2220 - 2229.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. Nguyen, R. C. Marcellus, A. Roulston, M. Watson, L. Serfass, S. R. Murthy Madiraju, D. Goulet, J. Viallet, L. Belec, X. Billot, et al.
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis
PNAS, December 4, 2007; 104(49): 19512 - 19517.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.